Revista da Associacao Medica Brasileira (1992)
-
[This corrects the article doi: 10.1590/1806-9282.20220147].
-
Rev Assoc Med Bras (1992) · Jul 2022
Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.
Irinotecan-based combination chemotherapies in malignant gliomas need to be examined. The aim of this study was to investigate the synergetic effect of ellagic acid, a natural polyphenolic antioxidant compound, with irinotecan, an inhibitor of topoisomerase I enzyme, on the growth, cadherin switch, and angiogenic processes of a glioma cell line. ⋯ Further research is required to prove a negative relationship between C6 glial cell proliferation and irinotecan with ellagic acid application. Our preliminary data suggest that even with the extremely short-term application, irinotecan with ellagic acid may affect glioma cells at the level of gene and protein expression.